Peringatan Keamanan

Panitumumab was shown to cause skin, ocular and mucosal related toxicities in 90% of patients receiving panitumumab. Subsequent to the development of severe dermatologic toxicities, infectious complications, including sepsis, septic death, and abscesses requiring incisions and drainage, were reported.

Panitumumab

DB01269

biotech approved investigational

Deskripsi

Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.

Panitumumab was granted FDA approval on 27 September 2006.L17663

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 7.5 days (range: 4-11 days)
Volume Distribusi -
Klirens (Clearance) * 4.9+/- 1.4 mL/kg/day [Following single-dose administrations of panitumumab as 1-hour infusions]

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

411 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Panitumumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Panitumumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Panitumumab.
Estrone Estrone may increase the thrombogenic activities of Panitumumab.
Estradiol Estradiol may increase the thrombogenic activities of Panitumumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Panitumumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Panitumumab.
Mestranol Mestranol may increase the thrombogenic activities of Panitumumab.
Estriol Estriol may increase the thrombogenic activities of Panitumumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Panitumumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Panitumumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Panitumumab.
Tibolone Tibolone may increase the thrombogenic activities of Panitumumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Panitumumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Panitumumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Panitumumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Panitumumab.
Zeranol Zeranol may increase the thrombogenic activities of Panitumumab.
Equol Equol may increase the thrombogenic activities of Panitumumab.
Promestriene Promestriene may increase the thrombogenic activities of Panitumumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Panitumumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Panitumumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Panitumumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Panitumumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Panitumumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Panitumumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Panitumumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Panitumumab.
Formononetin Formononetin may increase the thrombogenic activities of Panitumumab.
Estetrol Estetrol may increase the thrombogenic activities of Panitumumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Panitumumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Panitumumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Panitumumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Panitumumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Panitumumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Panitumumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Panitumumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Panitumumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Panitumumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Panitumumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Panitumumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Panitumumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Panitumumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Panitumumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Panitumumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Panitumumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Panitumumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Panitumumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Panitumumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Panitumumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Panitumumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Panitumumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Panitumumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Panitumumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Panitumumab.
Ranibizumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Ranibizumab.
Galiximab The risk or severity of adverse effects can be increased when Panitumumab is combined with Galiximab.
Pexelizumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Pexelizumab.
Afelimomab The risk or severity of adverse effects can be increased when Panitumumab is combined with Afelimomab.
Epratuzumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Epratuzumab.
Bectumomab The risk or severity of adverse effects can be increased when Panitumumab is combined with Bectumomab.
Oregovomab The risk or severity of adverse effects can be increased when Panitumumab is combined with Oregovomab.
IGN311 The risk or severity of adverse effects can be increased when Panitumumab is combined with IGN311.
Adecatumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Adecatumumab.
Labetuzumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Labetuzumab.
Matuzumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Matuzumab.
Fontolizumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Fontolizumab.
Bavituximab The risk or severity of adverse effects can be increased when Panitumumab is combined with Bavituximab.
CR002 The risk or severity of adverse effects can be increased when Panitumumab is combined with CR002.
Rozrolimupab The risk or severity of adverse effects can be increased when Panitumumab is combined with Rozrolimupab.
Girentuximab The risk or severity of adverse effects can be increased when Panitumumab is combined with Girentuximab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Panitumumab is combined with Obiltoxaximab.
XTL-001 The risk or severity of adverse effects can be increased when Panitumumab is combined with XTL-001.
NAV 1800 The risk or severity of adverse effects can be increased when Panitumumab is combined with NAV 1800.
Briakinumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Briakinumab.
Otelixizumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Otelixizumab.
AMG 108 The risk or severity of adverse effects can be increased when Panitumumab is combined with AMG 108.
Iratumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Iratumumab.
Enokizumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Enokizumab.
Ramucirumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Ramucirumab.
Farletuzumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Farletuzumab.
Veltuzumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Veltuzumab.
Ustekinumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Ustekinumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Panitumumab is combined with Trastuzumab emtansine.
PRO-542 The risk or severity of adverse effects can be increased when Panitumumab is combined with PRO-542.
TNX-901 The risk or severity of adverse effects can be increased when Panitumumab is combined with TNX-901.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Panitumumab is combined with Inotuzumab ozogamicin.
RI 624 The risk or severity of adverse effects can be increased when Panitumumab is combined with RI 624.
Stamulumab The risk or severity of adverse effects can be increased when Panitumumab is combined with MYO-029.
CT-011 The risk or severity of adverse effects can be increased when Panitumumab is combined with CT-011.
Leronlimab The risk or severity of adverse effects can be increased when Panitumumab is combined with Leronlimab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Panitumumab is combined with Glembatumumab vedotin.
Olaratumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Olaratumab.
IPH 2101 The risk or severity of adverse effects can be increased when Panitumumab is combined with IPH 2101.
TB-402 The risk or severity of adverse effects can be increased when Panitumumab is combined with TB-402.
Caplacizumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Caplacizumab.
IMC-1C11 The risk or severity of adverse effects can be increased when Panitumumab is combined with IMC-1C11.
Eldelumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Eldelumab.
Lumiliximab The risk or severity of adverse effects can be increased when Panitumumab is combined with Lumiliximab.
Canakinumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Canakinumab.

Target Protein

Epidermal growth factor receptor EGFR

Referensi & Sumber

Artikel (PubMed)
  • PMID: 14967460
    Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM: Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90.
  • PMID: 11255078
    Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001 Apr;38(1):17-23.
  • PMID: 18343240
    Wu M, Rivkin A, Pham T: Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Ther. 2008 Jan;30(1):14-30. doi: 10.1016/j.clinthera.2008.01.014.
  • PMID: 17355997
    Saadeh CE, Lee HS: Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer. Ann Pharmacother. 2007 Apr;41(4):606-13. Epub 2007 Mar 13.
  • PMID: 20481659
    Keating GM: Panitumumab: a review of its use in metastatic colorectal cancer. Drugs. 2010 May 28;70(8):1059-78. doi: 10.2165/11205090-000000000-00000.

Contoh Produk & Brand

Produk: 9 • International brands: 0
Produk
  • Vectibix
    Injection • 200 mg/10mL • Intravenous • US • Approved
  • Vectibix
    Solution • 100 mg/5mL • Intravenous • US • Approved
  • Vectibix
    Solution • 400 mg/20mL • Intravenous • US • Approved
  • Vectibix
    Solution • 100 mg / 5 mL • Intravenous • Canada • Approved
  • Vectibix
    Solution • 200 mg / 10 mL • Intravenous • Canada • Approved
  • Vectibix
    Solution • 400 mg / 20 mL • Intravenous • Canada • Approved
  • Vectibix
    Injection, solution, concentrate • 20 mg/ml • Intravenous • EU • Approved
  • Vectibix
    Injection, solution, concentrate • 20 mg/ml • Intravenous • EU • Approved
Menampilkan 8 dari 9 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul